p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lung carcinomas show frequent inactivation of the p53 tumor suppressor, which regulates an apoptotic pathway. The objective of the current study was to assess how the p53 apoptotic pathway is altered in nonsmall cell lung carcinoma (NSCLC), especially in tumors without p53 alterations. METHODS: p53, its upstream regulators (p14 ARF and HDM2), and downstream effectors of the apoptotic pathway (BAX and BCL2) were studied in 118 NSCLC specimens. p53 was analyzed by single‐stranded conformation polymorphism analysis covering exons 2–11 and by immunohistochemistry (IHC). p14 ARF was analyzed by methylation‐specific polymerase chain reaction and IHC. HDM2 was analyzed using Southern blot analysis and IHC. BAX and BCL2 were analyzed by IHC. Two other upstream regulators that regulate the stability of HDM2, PTEN and HAUSP, also were studied. RESULTS: Of 118 NSCLC specimens that were analyzed, p53 alterations were detected in 74 tumors (63%), p14 ARF inactivation was detected in 53 tumors (45%), and overexpression of HDM2 was found in 31 tumors (26%), including 6 tumors with gene amplification. Although p53 inactivation and HDM2 overexpression were detected simultaneously, HDM2 gene amplification was observed only in tumor specimens without p53 mutations. IHC revealed PTEN down‐regulation in 22 of 88 tumors (25%). HAUSP Northern blot analysis demonstrated several‐fold differences in gene expression that did not correlate with p53 alterations. Of 118 NSCLC specimens, expression of BAX and BCL2 expression were detected in 46 tumors (39%) and 17 tumors (14%), respectively. Finally, ASPP1 and ASPP2, molecules involved in mediating the transcription function of p53, were not found to be aberrantly expressed when tested by Northern blot analysis. CONCLUSIONS: Overall, two or more p53 pathway components were found to be frequently altered in patients with NSCLC. Greater than 90% of the alterations were due to abnormalities of p53, p14 ARF, or HDM2. Therefore, the inactivation of one or more components of the p53 pathway appears to be a prerequisite for the development of most NSCLCs. Cancer 2004. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Mayo, L. D., & Donner, D. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181181198 · Cited by 1,230
ASPP Proteins Specifically Stimulate the Apoptotic Function of p53
Samuels-Lev, Y., O'Connor, D. J., Bergamaschi, D., Trigiante, G., Hsieh, J.-K., Zhong, S., Campargue, I., Naumovski, L., Crook, T., & Lu, X. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00367-7 · Cited by 664 · cited 1×
“ASPP is a family of proteins, including ASPP1 and ASPP2, that enhance DNA binding and the transactivation function of p53 on proapoptotic genes, particularly BAX in vivo.(20) Therefore, ASPP is believed to regulate the affinity between p53 and the BAX gene promoter and its expression is frequently down-regulated in hu…”
BackgroundSherr, C. J., & Weber, J. D. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00038-6 · Cited by 654
Cited by
Mouse models for human lung cancer
Meuwissen, R., & Berns, A. (2005) · Genes & Development · doi:10.1101/gad.1284505 · Cited by 302
Rayburn, E., Zhang, R., He, J., & Wang, H. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332636 · Cited by 265
Inactivation of HAUSP in vivo modulates p53 function.
Kon, N., Kobayashi, Y., Li, M., Brooks, C. L., Ludwig, T., & Gu, W. (2010) · Oncogene · doi:10.1038/onc.2009.427 · Cited by 176
“This is supported by the observation that no hausp mutations were identified when surveying mutations in non-smallcell lung carcinomas, suggesting that complete loss of Hausp function is unfavorable for tumor growth (Mori et al., 2004).”
Fukui, T., Kondo, M., Ito, G., Maeda, O., Sato, N., Yoshioka, H., Yokoi, K., Ueda, Y., Shimokata, K., & Sekido, Y. (2005) · Oncogene · doi:10.1038/sj.onc.1208777 · Cited by 172
“…of heterozygosity (LOH) in lung cancer, with each targeted TSG identified subsequently, including 17p13 for p53, 9p21 for p14ARF and p16INK4a, 13q14 for RB, and multiple loci of 3p for FHIT, RASSF1A, and/or other unidentified genes (Sekido et al., 2002, 2003; Mori et al., 2004; Ito et al., 2005).”
BackgroundSelf-citationEmerging insights into HAUSP (USP7) in physiology, cancer and other diseases.
Bhattacharya, S., Chakraborty, D., Basu, M., & Ghosh, M. K. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0012-y · Cited by 162
“In the context of cancer, no effective mutations in the HAUSP gene have been identified to date, suggesting that its loss or gain of function may not be favorable for tumor growth.(35,36) To further support this fact, in a mouse model, HAUSP knockout in vivo stabilizes p53, leading to growth arrest and embryonic letha…”
BackgroundMasuya, D., Huang, C., Liu, D., Nakashima, T., Yokomise, H., Ueno, M., Nakashima, N., & Sumitomo, S. (2006) · The Journal of Pathology · doi:10.1002/path.1931 · Cited by 103
“There was no correlation between HAUSP mRNA expression and p53 gene status, as reported previously [28].”
BackgroundResultSato, N., Fukui, T., Taniguchi, T., Yokoyama, T., Kondo, M., Nagasaka, T., Goto, Y., Gao, W., Ueda, Y., Yokoi, K., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22328 · Cited by 56
Self-citation
Metadata
- Authors
- Mori, S., Ito, G., Usami, N., Yoshioka, H., Ueda, Y., Kodama, Y., Takahashi, M., Fong, K. M., Shimokata, K., & Sekido, Y.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-03-18
- Volume
- 100
- Issue
- 8
- Pages
- 1673-1682
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1968749685
- Cited by
- 76
- References
- 4
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.